Abstract
Some general aspects of the present role of serum tumour markers in clinical practice are discussed. The potential use of the described markers is hampered by the facts that the production of the markers is neither confined to the malignant tumour cell nor connected to the malignant phenotype. The main conclusions are: Serum tumour markers are not applicable as screening tests. Serum tumour markers can be of diagnostic value in some clinical situations, and have prognostic value in a few malignant tumours. The greatest value, still not fully exploited, is in the assessment of therapy in advanced disease. The true importance of the serum tumour markers can only be tested in carefully designed, prospective and randomized clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Scandinavian Journal of Clinical and Laboratory Investigation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
